<DOC>
	<DOCNO>NCT02755675</DOCNO>
	<brief_summary>uPAR PET/CT prognostic marker non-small cell lung cancer .</brief_summary>
	<brief_title>uPAR-PET Prognostication Patients With Non-small Cell Lung Cancer , Malignant Pleural Mesothelioma Large Cell Neuroendocrine Carcinoma Lung</brief_title>
	<detailed_description>Study I : uPAR PET/CT 68Ga-NOTA-AE105 evaluate prognostic tool patient non-small cell lung cancer ( NSCLC ) ( stage IV ( Ia ) operable disease ( Ib ) ) observer-blinded reading compare prognostic performance FDG PET/CT prognostic biomarkers uPAR . Furthermore , uPAR PET/CT evaluate pilot study patient malignant pleural mesothelioma ( MPM ) ( Study II ) large cell neuroendocrine carcinoma lung ( LCNEC ) ( Study III ) correlate immunohistochemical uPAR expression .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Study I Histologically verify NSCLC ( Study I ) Stage IV disease Operable disease The participant must capable understand give full inform write consent Study II Histologically verify MPM ( Study II ) The participant must capable understand give full inform write consent Study III Histologically verify LCNEC ( Study III ) The participant must capable understand give full inform write consent Study I , II , III Pregnancy Lactation/breast feeding Treatment neoadjuvant chemotherapy Weight 140 kg Allergy 68GaNOTAAE105</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>